Neurocrine Biosciences, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2008 | — | $36.8M | $68.5M |
| FY2009 | — | $4.0M | $37.3M |
| FY2010 | — | $19.3M | $54.1M |
| FY2011 | — | $60.1M | $50.1M |
| FY2012 | — | $154.4M | $63.8M |
| FY2013 | — | $120.4M | $44.8M |
| FY2014 | — | $208.7M | $31.0M |
| FY2015 | — | $424.5M | $74.2M |
| FY2016 | — | $314.9M | $83.3M |
| FY2017 | — | $372.2M | $254.7M |
| FY2018 | — | $480.8M | $141.7M |
| FY2019 | — | $636.9M | $112.3M |
| FY2020 | — | $1.13B | $187.1M |
| FY2021 | — | $1.37B | $340.8M |
| FY2022 | — | $1.71B | $262.9M |
| FY2023 | — | $2.23B | $251.1M |
| FY2024 | — | $2.59B | $233.0M |
| FY2025 | — | $3.25B | $713.0M |